Description

Zoledronic Acid for Injection / Infusion

Healthy Inc is a specialized global supplier and exporter of advanced bone metabolism and oncology support therapies. We provide high-purity Zoledronic Acid Injection (4 mg / 5 ml Concentrate & 5 mg / 100 ml Ready-to-Infuse), manufactured in WHO–GMP certified sterile aseptic facilities. This “Osteoclast Inhibitor” is a mandatory export to oncology centers, orthopedic hospitals, and government health ministries in Africa, LATAM, and Southeast Asia, serving as a powerful intervention for bone metastases, hypercalcemia of malignancy, and severe osteoporosis.

Product Overview

This formulation contains Zoledronic Acid, a highly potent, nitrogen-containing bisphosphonate.

The “Bone Resorption Blocker” Specialist:

• Mechanism (FPP Synthase Inhibition): Zoledronic Acid binds strongly to hydroxyapatite crystals in the bone matrix, specifically localizing at sites of high bone turnover. When osteoclasts (bone-destroying cells) attempt to resorb the bone, they ingest the drug. Inside the osteoclast, Zoledronic Acid inhibits the enzyme farnesyl pyrophosphate (FPP) synthase within the mevalonate pathway. This disrupts cellular signaling, causing rapid osteoclast apoptosis (cell death) and halting the destruction of bone tissue.
• Oncology Support (4 mg Dose): Tumors that metastasize to the bone (like breast and prostate cancer) or blood cancers (like multiple myeloma) hyper-stimulate osteoclasts, causing severe skeletal-related events (SREs) like pathological fractures and dangerous calcium leakage into the blood (hypercalcemia). Zoledronic Acid aggressively suppresses this process.
• Osteoporosis Management (5 mg Dose): For postmenopausal or glucocorticoid-induced osteoporosis, a single annual infusion dramatically increases bone mineral density and significantly reduces the risk of hip and vertebral fractures.

Product Composition & Strength

We supply this product in two distinct, specialty-specific presentations.

*Pack Sizes: Single 5 ml Vial (Oncology) or Single 100 ml IV Bottle (Osteoporosis).

Technical & Logistics Specifications

Critical data for Pharmaceutical Importers and Distributors.

Manufacturing Authority

Marketed and Distributed by Healthy Inc from WHO-GMP & ISO 9001:2015 certified units.

• Sterile Liquid Formulation: Manufactured under rigorous Grade A aseptic conditions. The 5 mg/100 ml presentation is terminally sterilized or aseptically filled into specialized infusion bottles, guaranteeing an absolutely pyrogen-free profile for direct systemic administration.
• pH and Stability Control: Zoledronic Acid must be maintained within a precise pH range (approx. 6.0 to 7.0) to ensure complete solubility and prevent micro-precipitation during the extended shelf-life of 24 to 36 months.

Therapeutic Indications (Human Use)

Indicated for the treatment of severe bone disorders and oncology complications:

• Hypercalcemia of Malignancy (HCM): Rapid reduction of critically high serum calcium levels caused by tumor activity (4 mg dose).
• Bone Metastases & Multiple Myeloma: Prevention of skeletal-related events (pathological fractures, spinal compression) in patients with advanced malignancies involving bone (4 mg dose).
• Osteoporosis: Treatment of postmenopausal women, and men, at high risk of fracture (5 mg dose administered once a year).
• Paget’s Disease of Bone: Treatment of patients with elevated serum alkaline phosphatase (5 mg dose).

Dosage & Administration

Recommended Dosage (Strictly as per Oncologist/Rheumatologist):

• Route: Intravenous (IV) Infusion ONLY. (Never administer as a rapid IV push or bolus).
• Oncology Dose (4 mg): Administered every 3 to 4 weeks. The 4 mg concentrate MUST be diluted in 100 ml of sterile 0.9% NaCl or 5% Dextrose and infused over no less than 15 minutes.
• Osteoporosis Dose (5 mg): Administered as a single 5 mg/100 ml IV infusion exactly once a year, infused over no less than 15 minutes.
• Hydration Protocol: Patients MUST be adequately hydrated (often with IV saline) prior to and following the administration of Zoledronic Acid to prevent acute renal failure.

Safety Warnings (CRITICAL):

• Renal Toxicity: Zoledronic acid can cause severe nephrotoxicity and acute renal failure, particularly if infused too rapidly (under 15 minutes) or in dehydrated patients. Serum creatinine must be monitored before every dose.
• Osteonecrosis of the Jaw (ONJ): BLACK BOX WARNING EQUIVALENT. Severe, localized death of the jaw bone can occur, particularly in oncology patients undergoing invasive dental procedures (like tooth extractions) while on the drug. A dental exam is mandatory prior to initiating therapy.
• Severe Hypocalcemia: Because it rapidly halts bone resorption, it can cause dangerous drops in blood calcium levels. Patients (especially in osteoporosis protocols) must be supplemented with oral calcium and Vitamin D.
• Atypical Femur Fractures: Long-term use (>3-5 years) for osteoporosis has been linked to rare, atypical, low-trauma fractures of the femoral shaft.

Global Export & Contract Manufacturing Services

Healthy Inc stands as a premier Pharmaceutical Exporter in India, dedicated to serving the needs of international Pharma Traders, Wholesalers, and Bulk Drug Distributors. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) services for Oncology Support and Orthopedic Injectables, allowing brands to launch high-quality generic medicines under their own label. Whether you are looking for a reliable Hospital Tender Supplier for government procurement in Africa or a B2B Pharma Marketplace partner for Latin America, our logistics network ensures timely delivery. We actively support Pharmaceutical Drop Shipping models and bulk indenting, ensuring that every Generic Medicine Wholesaler receives WHO-GMP certified products at competitive rates.